What Happens on Mounjaro Day 3?

Why day 3 often feels like the hardest part of week one

The SURMOUNT-1 trial (2,539 adults, 72 weeks, published in the New England Journal of Medicine) found that gastrointestinal side effects were the most commonly reported adverse events with tirzepatide, and that they clustered most heavily around the start of treatment and around each subsequent dose increase. Day 3 lands right in that window. Your body is encountering a dual GIP and GLP-1 receptor agonist for the first time, your gastric emptying is measurably slower, and fullness signals are arriving earlier than usual. The result for many people: a queasy, low-appetite morning, some fatigue, maybe a headache.

That is not a sign something has gone wrong. It is largely the mechanism working as expected. The stomach-slowing effect that will, over months, contribute to meaningful weight reduction is the same effect that causes queasiness in week one. For most people, days 4 and 5 feel noticeably more manageable, and you can get a clearer sense of what to expect by reading about the Mounjaro day 5 experience before you get there. You can read a fuller account of how this unfolds across the Mounjaro day-by-day experience if you want to see the broader pattern.

Small practical things tend to help: eating bland, low-fat, smaller meals; staying well hydrated; avoiding lying down immediately after eating. None of these replace your prescriber's advice, they are widely reported habits among people who navigate early treatment comfortably.

What the 2.5 mg dose is actually doing on day 3

The starter dose of tirzepatide is 2.5 mg, and it is worth being clear about its purpose. It is not the dose at which significant weight loss is expected. Its job is to let the GI system acclimatise, to reduce the chance that nausea, vomiting or diarrhoea arrives at full force. The NHS medicines page for tirzepatide confirms this: treatment begins at 2.5 mg and is escalated by a prescriber, typically in four-week steps, toward the dose range where weight-loss effects become clinically meaningful.

On day 3, you have had three injections if weekly or just the one from day 1 working through its first week. Tirzepatide has a long half-life (roughly five days) so blood concentrations are still building toward a steady state. Some people feel very little on day 3. Others feel a pronounced difference in hunger within 48 hours of their first injection. Both experiences sit within the normal range seen in trials. Appetite reduction is often the first effect noticed; weight changes take longer to appear on a scale, and comparing days rather than weeks tends to produce anxiety rather than useful information.

If you are curious about how the first few days compare as a sequence, the day 2 experience covers what typically precedes this point.

Side effects to watch for, and the signals that need prompt attention

On day 3, the side effects most likely to be present are nausea, reduced appetite, tiredness, and occasionally loose stools or constipation. These are consistent with what the SURMOUNT-1 data documented and with the prescribing information for tirzepatide. Mild nausea that passes within a few hours, or appetite that makes a full meal feel unappealing, is expected and not a reason to stop treatment without speaking to your prescriber first.

There are, however, symptoms that warrant prompt medical attention rather than waiting it out. Severe and persistent abdominal pain (particularly pain that radiates toward the back, with or without vomiting) should be assessed urgently, because acute pancreatitis, though infrequent, is a known risk with GLP-1 class medicines. The MHRA highlighted this in a Drug Safety Update in January 2026. Signs of significant dehydration from repeated vomiting or diarrhoea also need early medical review, as does any allergic reaction. You can report unexpected side effects directly through the MHRA Yellow Card scheme.

A question our prescribers hear regularly: "should I take the next injection if I still feel rough on day 3?" The answer depends on the severity of what you are experiencing. Mild ongoing nausea is not an automatic reason to delay. Severe, unmanageable symptoms are a conversation to have with your prescribing team before the next dose, not a decision to make alone by skipping it silently.

Getting the most from week one without overcomplicating it

Week one on tirzepatide is primarily about tolerability, not results. The clinical evidence from the SURMOUNT programme shows that weight outcomes accumulate over months (not days) and that the groundwork laid in the early weeks (developing habits around smaller portions, adequate protein and hydration) tends to shape how well people do later on. Day 3 is genuinely too early to draw conclusions about whether treatment is working.

One thing that catches some people out is the timing of when they started. If your first injection landed on a Monday, day 3 is a Wednesday, midweek, workday, no particular support around you. If it landed on a payday Friday when you had social plans, day 3 might have been harder than it needed to be. There is no perfect time to start, but knowing in advance that days 2 to 4 can be the most unsettled helps with planning. The Mounjaro step-by-step guide covers preparation in more detail.

For context on what the treatment costs as a private prescription, and what a legitimate price actually includes, the Mounjaro pricing guide is worth a read before you make any decisions. And if you are still weighing up which treatment suits your situation, the weight-loss overview sets out the options clearly. When you are ready to speak to someone clinically, our prescribers are available seven days a week, start a free consultation and a named clinician will review your case the same day.